Latest News
DTx Pharma to Present at Several Upcoming Virtual Events
SAN DIEGO, Nov. 25, 2020 PRNewswire – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be [...]
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
PR Newswire, San Diego – November 9, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of Denise Bevers as Chief Operating Officer. [...]
DTx Pharma to Present at the Virtual 7th Solebury Trout Fall Private Company Showcase
PR Newswire, San Diego – October 5, 2020 – DDTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, [...]
DTx Pharma to Present at the Chardan Virtual 4th Annual Genetic Medicines Event
PR Newswire, San Diego – September 28, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, [...]
DTx Pharma Receives New Funding Grant to Advance RNA-based Therapeutic Programs for Charcot-Marie Tooth (CMT)
-CMT is a genetic rare disease driven by the duplication of the PMP22 gene- PR Newswire, San Diego – September 21, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
DTx Pharma Announces Presentations at Several Upcoming Virtual Medical Meetings
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that the company will be presenting at several upcoming virtual medical meetings. Charles Allerson, Ph.D., DTx's VP of Chemistry, [...]